Evidence map›Paper›PMID 40895576›Full record

ArticleFrontiers in immunology2025

Differential modulation of SARS-CoV-2 infection by complement factor H and properdin.

Uday Kishore, Praveen M Varghese, Chandan Kumar, Susan Idicula-Thomas, Martin Mayora Neto, Anthony G Tsolaki, Pretty Ponnachan, Khaled Masmoudi, Basel Al-Ramadi, Manu Vatish and 3 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Uday KishoreDepartment of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates.
Praveen M VargheseDepartment of Clinical Microbiology, Umea University, Umea, Sweden.
Chandan KumarBiomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
Susan Idicula-ThomasBiomedical Informatics Centre, ICMR-National Institute for Research in Reproductive and Child Health, Mumbai, Maharashtra, India.
Martin Mayora NetoViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham, United Kingdom.
Anthony G TsolakiDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Pretty PonnachanDepartment of Veterinary Medicine (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates.
Khaled MasmoudiDepartment of Integrative Agriculture (CAVM), United Arab Emirates University, Al Ain, United Arab Emirates.
Basel Al-RamadiDepartment of Medical Microbiology and Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates.
Manu VatishNuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, United Kingdom.
Taruna MadanDepartment of Biosciences, College of Health, Medicine and Life Sciences, Brunel University London, Uxbridge, United Kingdom.
Nigel TempertonViral Pseudotype Unit, Medway School of Pharmacy, University of Kent and Greenwich, Chatham, United Kingdom.
Nazar BeiragDepartment of Clinical Microbiology, Umea University, Umea, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: An unbalanced immune response and excessive inflammation are the major hallmarks of severe SARS-CoV-2 infection, which can result in multiorgan failure and death. The dysregulation of the complement system has been shown in various studies as a crucial factor in the immunopathology of SARS-CoV-2 infection. Complement alternative pathway has been linked to the excessive inflammation in severe SARS-CoV-2 infection in which decreased levels of factor H (FH) and elevated levels of properdin (FP) were observed. The current study investigated the potential immune protective roles of FP and FH against SARS-CoV-2 infection. Methods: The interactions between FH and FP and the SARS-CoV-2 spike (S) and its receptor binding domain (RBD) were evaluated using direct ELISA. The cell binding and luciferase-based viral entry assays utilising S protein expressing lentiviral pseudotypes were used to evaluate the possible modulatory effects of FH, FP, and recombinant thrombospondin repeats 4 and 5 (TSR4 + 5) on SARS-CoV-2 cell entry. Using RT-qPCR, we also assessed the immunomodulatory roles of FH and FP in the cytokine response induced by SARS-CoV-2 pseudotypes. Results: FH and FP were found to bind to both the RBD and SARS-CoV-2 S proteins. The treatment of FP or TSR4 + 5 enhanced cell binding and entry of SARS-CoV-2 pseudotypes that was administered in A549 cells expressing human ACE2 and TMPRSS2 (A549-hACE2+TMPRSS2 cells). FP increases the affinity between host ACE2 and SARS-CoV-2, according to Discussion: These results imply that FH may function as a SARS-CoV-2 cell entry and binding inhibitor, reducing the inflammatory response linked to infection independently of complement activation. FP could aid cell viral entry and binding and aggravate hyperinflammation that might contribute to the severity of the infection.

Indexed as

Complement Factor HCOVID-19ProperdinSARS-CoV-2A549 CellsAngiotensin-Converting Enzyme 2HEK293 CellsHumansProtein BindingSerine EndopeptidasesSpike Glycoprotein, CoronavirusVirus InternalizationAngiotensin-Converting Enzyme 2CFH protein, humanComplement Factor HProperdinSerine EndopeptidasesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2alternative pathwaycomplement systemCOVID-19cytokine responsefactor Hinnate immune systemproperdinSARS-CoV-2

Identifiers

PMID40895576
PMCPMC12395051

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.